Completed PHASE3 INTERVENTIONAL NCT00139295

Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee

Comparison of the Efficacy and Safety of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee

Sponsor: Genzyme, a Sanofi Company

Conditions Osteoarthritis, Knee

Interventions Hylastan

Updated 6 times since 2017 Last updated: Feb 4, 2014 Started: Oct 31, 2004 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00139295, this PHASE3 trial focuses on Osteoarthritis, Knee and remains completed. Sponsored by Genzyme, a Sanofi Company, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Chicago, United States , Clearwater, United States , Conway, United States , Frederick, United States , Grants Pass, United States , Hamilton, Canada , Heidelberg, Germany , Lexington, United States , Leytonstone, United Kingdom and 13 more locations